Information for the public
Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy is available on the NHS. It is a possible first- or second-line treatment for metastatic colorectal cancer in adults, when:
- targeted treatments or immunotherapy are unsuitable
- chemotherapy would otherwise be offered.
An originator is the branded medicine that was originally licensed. A biosimilar medicine has a similar, but not identical, active ingredient to the originator, and is expected to be as safe and effective.
Targeted treatments find and attack cancer cells. Immunotherapy helps the immune system recognise and attack cancer cells.
Lines of treatment are a sequence of treatments, starting with the most suitable option and moving to alternatives if the first does not work or the condition gets worse. Each line can be a single drug or a combination of drugs.
If you are not eligible for bevacizumab but are already having it, you should be able to continue until you and your healthcare professional decide when best to stop.
Is this treatment right for me?
Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See our webpage on shared decision making.
Questions to think about
- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?
Information and support
The NHS webpage on bowel cancer may be a good place to find out more.
These organisations can give you advice and support:
- Bowel Cancer UK, 020 7940 1760
- Cancer Research UK, 0808 800 4040
- Macmillan Cancer Support, 0808 808 0000
You can also get support from your local Healthwatch.
NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.
ISBN: 978-1-4731-9293-5
This page was last updated: